Publications by authors named "Gary Chicchi"

Claim this Profile
D
Discovery of phenyl acetamides as potent and selective GPR119 agonists.
Cheng Zhu, Liping Wang, Yuping Zhu, Zack Zhiqiang Guo, Ping Liu, Gary Chicchi

Bioorg Med Chem Lett· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SAR exploration at the C-3 position of tetrahydro-β-carboline sstr3 antagonists.
Shuwen He, Peter H Dobbelaar, Liangqin Guo, Zhixiong Ye, Jian Liu, Gary G Chicchi

Bioorg Med Chem Lett· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel series of indazole-/indole-based glucagon receptor antagonists.
Songnian Lin, Fengqi Zhang, Guoqiang Jiang, Sajjad A Qureshi, Xiaodong Yang, Gary G Chicchi

Bioorg Med Chem Lett· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of substituted (4-phenyl-1H-imidazol-2-yl)methanamine as potent somatostatin receptor 3 agonists.
Zhong Lai, Shuwen He, Edward C Sherer, Zhicai Wu, Yang Yu, Gary G Chicchi

Bioorg Med Chem Lett· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of Potent and Orally Active GPR119 Agonists for the Treatment of Type II Diabetes.
Ping Liu, Zhiyong Hu, Byron G DuBois, Christopher R Moyes, David N Hunter, Gary Chicchi

ACS Med Chem Lett· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes.
Shrenik K Shah, Shuwen He, Liangqin Guo, Quang Truong, Hongbo Qi, Gary G Chicchi

ACS Med Chem Lett· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of Cardiovascular Effects of Tetrahydro-β-carboline sstr3 antagonists.
Shuwen He, Zhong Lai, Zhixiong Ye, Peter H Dobbelaar, Shrenik K Shah, Gary G Chicchi

ACS Med Chem Lett· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diamine Derivatives as Novel Small-Molecule, Potent, and Subtype-Selective Somatostatin SST3 Receptor Agonists.
Derun Li, Zhicai Wu, Yang Yu, Richard G Ball, Liangqin Guo, Gary G Chicchi

ACS Med Chem Lett· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents.
Jonathan W Day, Vasily Gelfanov, David Smiley, Paul E Carrington, George Eiermann, Gary Chicchi

Biopolymers· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-[(3aR,4R,5S,7aS)-5-{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxyethoxy}-4-(2-methylphenyl)octahydro-2H-isoindol-2-yl]-1,3-oxazol-4(5H)-one: a potent human NK1 receptor antagonist with multiple clearance pathways.
Andrew J Kassick, Jinlong Jiang, Jaime Bunda, David Wilson, Jianming Bao, Gary Chicchi

J Med Chem· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin.
Jennifer R Kosinski, James Hubert, Paul E Carrington, Gary G Chicchi, James Mu

Obesity (Silver Spring)· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential effects of oxyntomodulin and GLP-1 on glucose metabolism.
Xiaobing Du, Jennifer R Kosinski, Julie Lao, Xiaolan Shen, Aleksandr Petrov, Gary G Chicchi

Am J Physiol Endocrinol Metab· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes.
Shuwen He, Zhixiong Ye, Quang Truong, Shrenik Shah, Wu Du, Gary G Chicchi

ACS Med Chem Lett· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stimulation of Glucose-Dependent Insulin Secretion by a Potent, Selective sst3 Antagonist.
Alexander Pasternak, Zhe Feng, Reynalda de Jesus, Zhixiong Ye, Shuwen He, Gary G Chicchi

ACS Med Chem Lett· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of potent and selective GPR119 agonists for type II diabetes.
Jason W Szewczyk, John Acton, Alan D Adams, Gary Chicchi, Stanley Freeman

Bioorg Med Chem Lett· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fused tricyclic pyrrolizinones that exhibit pseudo-irreversible blockade of the NK1 receptor.
Gregori J Morriello, Gary Chicchi, Tricia Johnson, Sander G Mills, Julie Demartino

Bioorg Med Chem Lett· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tetrahydroindolizinone NK1 antagonists.
Jianming Bao, Huagang Lu, Gregori J Morriello, Emma J Carlson, Alan Wheeldon, Gary G Chicchi

Bioorg Med Chem Lett· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Substituted fused bicyclic pyrrolizinones as potent, orally bioavailable hNK1 antagonists.
Gregori J Morriello, Sander G Mills, Tricia Johnson, Mikhail Reibarkh, Gary Chicchi

Bioorg Med Chem Lett· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
Alessandro Pocai, Paul E Carrington, Jennifer R Adams, Michael Wright, George Eiermann, Gary G Chicchi

Diabetes· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent, brain-penetrant, hydroisoindoline-based human neurokinin-1 receptor antagonists.
Jinlong Jiang, Jaime L Bunda, Geoge A Doss, Gary G Chicchi, Marc M Kurtz

J Med Chem· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of basal and stress-induced amygdaloid substance P release by the potent and selective NK1 receptor antagonist L-822429.
Nicolas Singewald, Gary G Chicchi, Clemens C Thurner, Kwei-Lan Tsao, Mariana Spetea

J Neurochem· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fused bicyclic pyrrolizinones as new scaffolds for human NK1 antagonists.
Gregori J Morriello, Robert J Devita, Sander G Mills, Jonathan R Young, Peter Lin, Gary G Chicchi

Bioorg Med Chem· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.
Jonathan R Young, Ronsar Eid, Cherilyn Turner, Robert J DeVita, Marc M Kurtz, Gary G Chicchi

Bioorg Med Chem Lett· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of potent, selective, and orally bioavailable hNK1 antagonists derived from pyrrolidine.
Peter Lin, Lehua Chang, Robert J Devita, Jonathan R Young, Ronsar Eid, Gary G Chicchi

Bioorg Med Chem Lett· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists.
Jason M Elliott, Robert W Carling, Mark Chambers, Gary G Chicchi, Peter H Hutson

Bioorg Med Chem Lett· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis